Aalto Bio Reagents Announces 15 Pathogen Development Strategy to Solve the World's Future Diseases
Updated: Apr 6
Aalto Bio Reagents Ltd., a leading global developer of critical raw materials and reagents for the development of diagnostic tests, today announced its commitment to developing diagnostic targets to 15 of the world’s biggest health risk pathogens as identified by the World Health Organisation (WHO).
Aalto Bio Reagents (www.aaltobioreagents.com) has been a global leader in building and providing critical raw materials, including proteins, antigens, antibodies and biospecimens to IVD and therapeutic companies, as well as Vet Dx companies for more than 44 years. Aalto’s products are standard bearers in immunoassays, ELISA, chemiluminescence assays, lateral flow and POC as well as companion diagnostics.
Aalto Bio Reagents is the leading producer and provider of existing and emerging infectious disease pathogens. It is at the forefront of the earlier test development for diagnosis of Zika, Dengue, Chikungunya, West Nile, Yellow Fever and SARS viruses. Aalto Bio Reagents was the first to develop and market diagnostic materials for HIV-1 gp120 and p24, having over 15 years in the field and its HIV materials have over 100 International publications.
Aalto Bio has one of the most extensive product portfolios which includes native and recombinant antigens and monoclonal and polyclonal antibodies to many of the leading infectious diseases (https://www.aaltobioreagents.com/products). As the company continues to develop the next generation of infectious disease targets, it is adding some exciting new development materials to its Infectious Disease portfolio that include:
1. MERS CoV antigen
2. MERS CoV MAb
3. Nipah virus
4. Mayaro virus
5. Oropouche virus
6. Ebola Zaire strain antigen
7. Hendra virus
8. Lassa virus
9. Marburg virus
10. Rift Valley fever virus
11. SARS CoV-1 ( Korean strain )
12. Crimean-Congo hemorrhagic fever virus
13. Mycobacterium tuberculosis
14. Chikungunya virus
15. Zika virus
Aalto Bio also offers disease state human plasma products collected, tested and stored following a strict quality management system. Aalto Bio’s human disease state plasma units are collected, screened, processed, stored and shipped based on ethical considerations and customers' specific requirements. The company has agreements in place with all the major collection centres in Europe, U.S. and Canada as well as sources in Africa and LATAM. We can source pooled or individual patient samples and biospecimens prospectively or retrospectively for specific research needs for new and emerging diseases.
Aalto Bio Reagents will be attending the World Vaccine Congress April 19-21 in Washington DC and will be available to meet and discuss their new products with all their clients.
“Aalto Bio Reagents Ltd. remain on hand to help diagnostic manufacturers and vaccine developers around the globe meet their emerging disease diagnostic testing requirements as new variants and as new diseases emerge globally. Aalto will continue to build new critical materials as it has done since the outset of this COVID-19 world health crisis by delivering first-in-class critical raw material products. With the addition of the new 15 pathogen disease panel, Aalto will, as ever, collaborate with infectious disease scientists around the globe to build solutions for the emerging diseases of the future “ stated Philip Noone, CEO Aalto Bio Reagents.
About Aalto Bio Reagents
Founded in 1978, Aalto Bio Reagents is a leading developer and provider of raw materials to the in-vitro diagnostics industry and to research laboratories globally. The company serves the largest multinational companies in the industry with a broad range of purified human proteins; monoclonal and polyclonal antibodies; fungal, parasitic, bacterial and viral antigens; and disease state plasma for in-vitro diagnostic application.
Since the company's inception, it has built strong working relationships with its clients who trust Aalto to provide them with the highest quality raw materials to meet the exacting standards of their own product development requirements. Headquartered in Dublin, Ireland, the company is rapidly expanding both its product portfolio and customer base. For further information please visit http://www.aaltobioreagents.com
Contact: Aalto Bio Tel: +353-1-4900685 Email: firstname.lastname@example.org